|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Blockade of VEGFR2 sensitizes breast tumors to PD-1 blockade in a dose-dependent manner.
|
31848190 |
2019 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
One week after the third injection, the breast tumors of eight mice from each group were excised to analyze NF-κBp65' vascular endothelial growth factor receptor-2 (VEGFR2) and Pgp gene and protein expressions and the other seven mice were monitored for survival rate analysis until they died.
|
28937793 |
2017 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Furthermore, miR-497 exhibited anti-angiogenesis and anti-tumor effects in the VEGFR2-luc breast tumor model proven by BLI, WB and immunohistochemistry analysis.
|
26345385 |
2015 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors.
|
23649001 |
2013 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, the results from current study demonstrate that antagomir-21 can effectively suppress tumor growth and angiogenesis in VEGFR2-luc mouse breast tumor model and bioluminescent imaging can be used as a tool for noninvasively and continuously monitoring tumor angiogenesis in vivo.
|
23951172 |
2013 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
|
20135347 |
2010 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Expression of VEGF and VEGFR2 in tumors during neoadjuvant therapy of patients with breast cancer.
|
19023980 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study, we found that VEGF-A 165 (recombinant protein or breast tumor cell-secreted) is also capable of inducing migration of VEGFR2-negative human aortic smooth muscle cells (hAOSMCs), and this induction is mediated through a molecular cross-talk of neuropilin-1 (NRP-1), VEGFR1 (Flt-1), and phosphoinositide 3-kinase (PI3K)/Akt signaling kinase.
|
18284215 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
While vascular endothelial growth factor (VEGF) expression in breast tumors has been correlated with a poor outcome in the pathogenesis of breast cancer, the expression, localization, and function of VEGF receptors VEGFR1 (also known as FLT1) and VEGFR2 (also known as KDR or FLK1), as well as neuropilin 1 (NRP1), in breast cancer are controversial.
|
17550303 |
2007 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These novel findings suggest that targeting the release of VEGF from tumor epithelial cells as well as blocking interactions between VEGF and VEGFR-2 on both endothelial and tumor epithelial cells may facilitate the development of new antiangiogenic therapies for progestin-dependent breast tumors.
|
15845615 |
2005 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
These novel findings suggest that targeting the release of VEGF from tumor epithelial cells as well as blocking interactions between VEGF and VEGFR-2 on both endothelial and tumor epithelial cells may facilitate the development of new antiangiogenic therapies for progestin-dependent breast tumors.
|
15845615 |
2005 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation.
|
15170218 |
2004 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of the c-kit tyrosine kinase growth factor receptor has been reported in some breast tumors; however, no data exist concerning expression of its ligand, stem cell factor.
|
7545433 |
1995 |